Skip to main content

Table 3 Details of NGS analysis in 6 samples at lower RNA input level

From: Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report

Case# Specimen site Sample collection date RNA input (ng) Gene fusion No. valid fusion reads % of reads supporting fusion No. unique start sites Breakpoints
1 Parotid 2015 10 ETV6-NTRK3 8 13.56 3 chr12:12022903 chr15:88483984
     NTRK3-ETV6 6 10.17 3 chr15:88576088 chr12:12037379
2 Lymph node 2016 10 ETV6-NTRK3 212 70.20 96 chr12:12022903 chr15:88483984
     NTRK3-ETV6 76 48.41 44 chr15:88576088 chr12:12037379
3–1* Parotid 1994 10 ETV6-NTRK3 23 34.33 10 chr12:12022903 chr15:88483984
3–2* Parotid 2008 10 ETV6-NTRK3 8 15.38 4 chr12:12022903 chr15:88483984
3–3* Parotid 2012 10 ETV6-NTRK3 779 55.25 162 chr12:12022903 chr15:88483984
3–4* Lymph node 2012 10 ETV6-NTRK3 255 72.24 97 chr12:12022903 chr15:88483984
  1. *3–1, the initial tumor; 3–2, 3rd recurrence; 3–3, 5th recurrence; 3–4, and 6th recurrence of case 3, respectively
  2. Reciprocal fusion which is secondary and non –driver mutation